Change of target volume and its dosimetric impact during the course of accelerated partial breast irradiation using intraoperative multicatheter interstitial brachytherapy after open cavity surgery

Upreti, Ritu Raj; Budrukkar, Ashwini; Upreti, Udita; Misra, Shagun; Wadasadawala, Tabassum; Kohle, Satish; Deshpande, Deepak D.

doi:10.1016/j.brachy.2017.05.004

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When we administered high doses, we decided to restrain margins to 1 cm. In addition, it has been demonstrated that significative volume variations can be produced in 5 days treatments [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results

Latorre¹,

Galdós²,

Buznego³

et al. 2018

jcb

View full text Add to dashboard Cite

PurposeTo evaluate the feasibility of acute and chronic toxicity in patients suitable for accelerated partial breast irradiation (APBI) in a single 18 Gy fraction with multicatheter high-dose-rate (HDR) brachytherapy, as well as cosmetic and oncological outcomes.Material and methodsBetween September 2014 and March 2016, twenty consecutive patients with low-risk invasive and ductal carcinoma in situ were treated with interstitial multicatheter HDR brachytherapy in a single 18 Gy fraction.ResultsMedian age was 63.5 years (range, 51-79). Acute toxicity was observed in seven patients, while the pain during following days and hematoma were seen in four patients. With a median follow-up of 24 months, late toxicity was found in one patient with fat necrosis g2 and fibrosis g2 in another patient. The overall survival (OS) and locoregional control (LC) was 100%. Disease-free survival (DFS) and distant control was 95%. Good to excellent cosmetic outcomes were noted in 80% of patients and fair in 4 patients (20%).ConclusionsThis is the first report in the medical literature that focuses on feasibility and acute and chronic toxicity, with a median follow-up of 24 months (range, 20-40). The protocol is viable and convenient. However, a longer follow-up is needed to know chronic toxicity and oncologic outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%